Cargando…

Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient

BACKGROUND: Somatic mutations in Wilms' tumor 1 (WT1) and tet methylcytosine dioxygenase 2 (TET2) genes were separately perceived as contributors to hematopoietic disorders and usually thought to have a mutually exclusive effect in acute myeloid leukemia (AML). However, we found novel WT1 and T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Qiang, Guo, Yixian, Lan, Xiaoxi, Wang, Guoxiang, Sun, Wanling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201863/ https://www.ncbi.nlm.nih.gov/pubmed/34120595 http://dx.doi.org/10.1186/s12920-021-01002-0

Ejemplares similares

Better prognosis in POEMS patients with cerebral infarction before polyneuropathy
por: Lan, Xiaoxi, et al.
Publicado: (2022)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
por: Busse, Antonia, et al.
Publicado: (2010)

Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment
por: Bunaciu, Rodica P., et al.
Publicado: (2017)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Identification of Novel tet(X3) Variants Resistant To Tigecycline in Acinetobacter Species
por: Cheng, Yumeng, et al.
Publicado: (2022)

Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1
por: Das, Andrew B., et al.
Publicado: (2019)

Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways
por: Lyu, Y, et al.
Publicado: (2017)

WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies
por: Suzuki, Mikito, et al.
Publicado: (2019)

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Malagola, Michele, et al.
Publicado: (2014)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
por: Sayar, Hamid, et al.
Publicado: (2017)

Tet Enzymes, Variants, and Differential Effects on Function
por: Melamed, Philippa, et al.
Publicado: (2018)

Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia
por: Song, Huan, et al.
Publicado: (2022)

Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre‐leukaemic clone resulting in T2‐ALL and AML‐M0
por: Manchev, Vladimir T., et al.
Publicado: (2016)

Recurrent TET2 mutations in adult T cell leukemia
por: Marçais, Ambroise, et al.
Publicado: (2014)

Proteasomal degradation of WT proinsulin in pancreatic beta cells
por: Xu, Xiaoxi, et al.
Publicado: (2022)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy
por: van den Ancker, Willemijn, et al.
Publicado: (2013)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia
por: Pasca, Sergiu, et al.
Publicado: (2020)

Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis
por: Zhang, Donghui, et al.
Publicado: (2022)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

TTMV-RARA fusion as a recurrent cause of AML with APL characteristics
por: Sala-Torra, Olga, et al.
Publicado: (2022)

Microstructure and Hot Deformation Behavior of the Mg–8 wt.% Sn–1.5 wt.% Al Alloy
por: Sun, Zhaoqian, et al.
Publicado: (2021)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
por: Liu, Yifan, et al.
Publicado: (2023)

Relapsed or primary refractory AML: moving past MEC and FLAG-ida
por: Koenig, Kristin, et al.
Publicado: (2020)

Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy
por: Smith, Stephen M., et al.
Publicado: (2022)

Targeting AML through DR4 with a novel variant of rhTRAIL
por: Szegezdi, Eva, et al.
Publicado: (2011)

Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma
por: Gong, Fuxing, et al.
Publicado: (2016)

Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp.
por: Wang, Nannan, et al.
Publicado: (2021)

Endogenous epitope-tagging of Tet1, Tet2 and Tet3 identifies TET2 as a naïve pluripotency marker
por: Pantier, Raphaël, et al.
Publicado: (2019)

The -KTS splice variant of WT1 is essential for ovarian determination in mice
por: Gregoire, Elodie P, et al.
Publicado: (2023)

TET2 Variants in Japanese Patients With Pulmonary Arterial Hypertension
por: Hiraide, Takahiro, et al.
Publicado: (2021)

The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis
por: Long, Jianting, et al.
Publicado: (2016)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
por: Chen, Xiaotong, et al.
Publicado: (2023)

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
por: Tong, Juan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2c7sfln0gkjsurv8g57vc10fjg